文献速递前列腺癌

低危与极低危前列腺癌时代肾移植患者局限性前列腺癌的评估与积极治疗对比主动监测

Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.
PubMed 文献 · J Urol · 2019-08-08

综述肾移植候选者及受者的前列腺癌筛查、诊断与管理证据,聚焦终末期肾病患者前列腺癌发病率与诊断、移植前筛查建议、前列腺癌诊断后等待时间建议及移植后自然史。结论为移植前后前列腺癌筛查与管理尚无标准化指南,终末期肾病是重要竞争性死亡风险,主动监测作用尚待充分研究,需进一步研究及列线图整合风险分层方案。

要点

  • 移植前后前列腺癌筛查尚无标准化指南,终末期肾病为重要竞争性死亡风险。
  • 对任何前列腺癌患者积极治疗并等待5年再移植可能负面影响透析患者整体生存。
  • 低危前列腺癌主动监测在肾移植复杂病例中的作用尚待充分研究。

核心结论

  • 移植前后前列腺癌筛查与管理尚无标准化指南,终末期肾病是重要竞争性死亡风险,主动监测作用尚待充分研究,需进一步研究及列线图整合风险分层筛查与治疗方案。

研究设计与样本

  • 英文文献综述,检索词包括前列腺癌、终末期肾病、肾移植、前列腺癌筛查、前列腺特异性抗原、前列腺癌治疗和主动监测等组合。

主要发现

  • 几乎所有终末期肾病患者移植前后仍广泛进行前列腺癌筛查。
  • 对任何前列腺癌患者积极治疗并等待5年再移植可能负面影响参与者集合及透析患者整体生存。
  • 多个团队提出低危前列腺癌患者可缩短等待肾移植时间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 移植前后前列腺癌筛查与管理尚无标准化指南。
  • 主动监测在肾移植复杂病例中的作用尚待充分研究。
  • 需进一步研究及列线图整合风险分层筛查与治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Current trends in renal transplantation, such as improved allograft/recipient survival and expanded organ transplantation eligibility criteria in older recipients, are concomitant with increasingly detected low risk prostate cancer in candidates for or recipients of renal transplantation. We reviewed the evidence regarding prostate cancer screening, diagnosis and management in renal transplant candidates and recipients. We focused on published reports of prostate cancer incidence and diagnosis in patients with end stage renal disease, pretransplant screening recommendations, and recommendations regarding waiting time between treatment and active wait listing after the prostate cancer diagnosis in renal transplant candidates. In addition, we examined the natural history of prostate cancer development after renal transplantation in the setting of standard immunosuppression. MATERIALS AND METHODS: We reviewed the English language literature using search terms including prostate cancer, end stage renal disease, renal transplantation, prostate cancer screening, prostate specific antigen, prostate cancer treatment and active surveillance in various combinations. RESULTS: Prostate cancer screening is still widely done in almost all patients with end stage renal disease before and after transplantation. Active treatment of any patients with prostate cancer and a 5-year waiting period before transplantation can negatively affect the collective pool of participants and the overall survival of patients on dialysis. Several groups have proposed a shorter waiting time to kidney transplantation in patients with low risk prostate cancer. CONCLUSIONS: There are no standardized guidelines for screening and management of prostate cancer before and after transplantation. In the era of low risk prostate cancer end stage renal disease is a significant competing mortality risk factor. The role of active surveillance in these complex cases has yet to be well investigated. Further studies and nomograms are urged to integrate risk stratified screening and treatment protocols before and after renal transplantation.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Aminsharifi A, Simon R, Polascik TJ, et al. Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer. J Urol. 2019. PMID: 30835631. doi:10.1097/JU.0000000000000207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。